Stem-Cell Research: Drawing the Line
Lancet 358:163,217, Greenberg,D.S., 2001
Dementia in Cerebral Vascular Disease
Cerebral Vascular Diseases, Grunne & Stratton, Inc. , pp 232-236 (Edited by Toole & others), Fisher,C.M., 1968
Neurodegenerative causes of death among retired National Football League Players
Neurol 79:1970-1974, Lehman, E.,et al, 2012
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
CSF biomarkers in posterior cortical atrophy
Neurol 76:1782-1788, Seguin, J.et al, 2011
Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD
Neurol 75:143-151, Vemuri,P., et al, 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Genetic Aspects of Alzheimer Disease
The Neurologist 15:80-86, Williamson,J.,et al, 2009
CSF Biomarkers and Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment
JAMA 302:385-393,436,452, Mattsson,N.,et al, 2009
NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type
Neurol 70:17-24, Szekely,C.A.,et al, 2008
Joint Effect of Stroke and APOE 4 on Dementia Risk: The Canadian Study of Health and Aging
Neurol 70:9-16,5, Jin,Y.P.,et al, 2008
DHEA Treatment of Alzheimer's Disease
Neurol 60:1071-1076,1060, Wolkowitz,O.M.,et al, 2003
Leisure Activities and the Risk of Dementia in the Elderly
NEJM 348:2508-2516, Verghese,J.,et al, 2003
Evaluation of CSf-tau and CSF-AB42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Arch Neurol 58:373-379,349, Andreasen,N.,et al, 2001
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
Longitudinal Study of CSF Levels of Tau, A beta 1-40, and A beta 1-42 (43) in Alzheimer's Disease
Ann Neurol 44:17-26, 61998., Kanai,M.,et al, 1998
Atrial Fibrillation and Dementia in a Population-Based Study, The Rotterdam Study
Stroke 28:316-321, Ott,A.,et al, 1997
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Assessment of CSF Levels of Tau Protein in Mildly Demented Patients with Alzheimer's Disese
Neurol 48:632-635, Galasko,D.,et al, 1997
Genetic Testing for Alzheimer Disease, Practical and Ethical Issues
Arch Neurol 54:1226-1229, Roses,A.D., 1997
Preexisting Dementia in Stroke Patients, Baseline Frequency, Associated Factors, & Outcome
Stroke 28:2429-2436, Henon,H.,et al, 1997
Assessment of Brain SPECT:Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 46:278-285, , 1996
Apolipoprotein E Genotyping in Alzheimer's Disease
Lancet 347:1091-1095, Tanzi,R.,et al, 1996
Genetic Factors in Alzheimer's Disease:A Review of Recent Advances
Ann Neurol 40:829-840, Levy-Lahad,E.&Bird,T.D., 1996
Elevated Risk of Alzheimer's Disease Among Workers with Likely Electromagnetic Field Exposure
Neurol 47:1477-1481, Sobel,E.,et al, 1996
Synergistic Effects of Traumatic Head Injury and Apolipoprotein-E4 In Patients with Alzheimer's Disease
Neurol 45:555-557, Mayeux,R.,et al, 1995
Prospective CT Confirms Differnces Between Vascular and Alzheimer's Dementia
Stroke 26:735-742, Meyer,J.S.,et al, 1995
Apolipoprotein E Allele E4, Dementia, and Cognitive Decline in a Population Sample
Lancet 346:1387-1390, Henderson,A.S.,et al, 1995
Statement of Use of Apolipoprotein E Testing for Alzheimer Disease
JAMA 274:1627-1629, Farrer,L.A.,et al, 1995
Apoliprprotein E E4 Allele & the Lifetime Risk of Alzheimer's Disease:What Physicians Know, & What They Should Know
Arch Neurol 52:1074-1079, Seshadri,S.,et al, 1995
Apolipoprotein E Genotype in Patients with Alzheimer's Disease:Implications for Risk of Dementia Among Relatives
Ann Neurol 38:797-808, Farrer,L.A.,et al, 1995
Medical Aspects of the Persistent Vegetative State
NEJM 330:1499-1508, 1572-15791994., Annas,G.J.,et al, 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Brain Single-Photon Emission Computed Tomography
Neurol 44:1970-1977, Masdeu,J.C.,et al, 1994
A Population-Based Study of Dementia in 85-Year-Olds
NEJM 328:153-158, 203-2051993., Skoog,I.,et al, 1993
End-State Alzheimer's Disease:Glasgow Coma Scale and the Neurologic Examination
Arch Neurol 50:1309-1315, Benesch,C.G.,et al, 1993
The Older Driver, Clinical Assessment and Injury Prevention
Arch Int Med 152:735-740, Underwood,M., 1992
Murder, Insanity, and Medical Expert Witnesses
ARch Neurol 49:608-611, Ciccone,J.R., 1992
Anomalous Molecular Form of Acetylcholinesterase in CSF in Histologically Diagnosed Alzheimer's Disease
Lancet 337:447-450, Navaratnam,D.S.,et al, 1991
Clinical Characteristics of Patients in the Persistent Vegetative State
Arch Int Med 151:930-932, 855-8561991., Tresch,D.D.,et al, 1991
Assessment of Competency:The Role of Neurobehavioral Deficits
Ann Int Med 115:203-208, Freedman,M.,et al, 1991
BA4 Amyloid Protein Deposition in Brain After Head Trauma
Lancet 338:1422-1423, Roberts,G.W.,et al, 1991
Clinical Genetics and Genetic Counseling in Alzheimer Disease
Ann Int Med 115:601-606, Breitner,J.C.S., 1991
Single-Photon Emission Computed Tomography (SPECT)
JAMA 263:561-564, Holman,B.L.&Tumeh,S.S., 1990
Immunocytochemistry of Neurofibrillary Tangles in Dementia Pugilistica and Alzheimer's Disease:Evidence for Common Genesis
Lancet 2:1456-1458, Roberts,G.W., 1988
Cerebral Amyloid Angiopathy, A Critical Review
Stroke 18:311-324, Vinters,H.V., 1987